한글목차

세계의 저분자량 헤파린 원료의약품 시장 규모는 2024년에 7억 3,000만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 8.0%로 성장하여 2031년까지 13억 9,100만 달러로 확대될 것으로 예측됩니다.

본 보고서는 저분자 헤파린 원료의약품의 국경 간 산업 발자국, 자본 배분 패턴, 지역 경제의 상호 의존성, 공급망 재구축, 최근 관세 조정 및 국제적인 전략적 대응 조치에 대한 종합적인 평가를 제공합니다.

헤파린은 항응고제(혈액을 묽게 하는 약제)로 혈전 형성을 방지합니다. 정맥, 동맥 또는 폐의 혈전 치료 및 예방에 사용됩니다. 또한, 수술 전 혈전 위험 감소에도 사용됩니다. 헤파린 제품의 대부분은 헤파린나트륨 또는 헤파린 칼슘의 형태로 존재합니다. 본 보고서에서는 주로 저분자량 헤파린 원료의약품(API)을 연구 대상으로 합니다.

저분자량 헤파린(LMWH) 원료의약품 시장은 심부정맥혈전증(DVT) 및 폐색전증(PE)과 같은 혈전 관련 질환의 예방 및 치료에 LMWH가 광범위하게 사용됨에 따라 세계 제약 산업에서 매우 중요한 역할을 하고 있습니다. LMWH API는 미분획 헤파린에 비해 우수한 약동학적 특성(높은 생체이용률, 긴 반감기, 부작용 위험 감소 등)을 가지고 있어 임상현장에서 우선적으로 사용되고 있습니다. 심혈관질환 및 정맥혈전색전증 유병률 증가, 고령화, 전 세계 수술 건수 증가 등이 LMWH 기반 치료법에 대한 수요를 크게 견인하고 있습니다.

혈전 관련 질환의 높은 유병률과 선진화된 의료 인프라로 인해 북미와 유럽 시장이 수요를 주도하고 있습니다. 아시아태평양은 의료비 지출 증가와 제네릭 의약품의 부상으로 성장 시장으로 부상하고 있습니다.

저분자량 헤파린 원료의약품 부문 시장에서 에녹사파린 나트륨은 2024년부터 2030년까지 연평균 12.46%로 성장하여 2030년까지 12억 5,882만 달러 규모에 달할 것으로 예상됩니다.

저분자량 헤파린 원료의약품의 세계 주요 기업으로는 Yantai Dongcheng Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Changzhou Qianhong Biopharma, Qingdao Jiulong Biopharmaceutical 등이 있습니다. 2023년 기준, 세계 상위 5개 기업의 매출 점유율은 약 72.91%를 차지하고 있습니다.

이 보고서는 저분자량 헤파린 원료 세계 시장에 대해 총 판매량, 매출액, 가격, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

저분자량 헤파린 원료의약품의 시장 규모 추정 및 예측은 판매량(10억 단위) 및 매출액(백만 달러)으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적 분석과 정성적 분석을 통해 독자들이 사업 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 저분자 헤파린 원료의약품에 대한 정보에 입각한 사업적 판단을 내릴 수 있도록 돕습니다.

시장 세분화

기업별

• Yantai Dongcheng Pharmaceutical
• Shenzhen Hepalink Pharmaceutical
• Nanjing King-friend
• Changzhou Qianhong Biopharma
• Qingdao Jiulong Biopharmaceutical
• Dongying Tiandong Pharmaceutical
• Yino Pharma
• Opocrin
• Hebei Changshan
• Hubei Enoray Biopharmaceutical
• Nanjing Nanda Pharmaceutical
• Cisen Pharmaceutical

유형별 부문

• 저분자량 헤파린 나트륨
• 저분자량 헤파린 칼슘

용도별 부문

• 에녹사파린 나트륨
• 나드로파린 칼슘
• 달테파린 나트륨
• 틴자파린 나트륨
• 파르나파린 나트륨

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동 및 아프리카

영문목차

The global market for Low Molecular Weight Heparin API was estimated to be worth US$ 730 million in 2024 and is forecast to a readjusted size of US$ 1391 million by 2031 with a CAGR of 8.0% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Low Molecular Weight Heparin API cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the low molecular weight heparin API.

The Low Molecular Weight Heparin (LMWH) API market plays a crucial role in the global pharmaceutical industry due to the widespread use of LMWHs in the prevention and treatment of blood clot-related disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). LMWH APIs are preferred in clinical settings for their favorable pharmacological properties, including better bioavailability, longer half-life, and reduced risk of side effects compared to unfractionated heparin. The increasing prevalence of cardiovascular diseases and venous thromboembolism, aging populations, and a rise in surgical procedures worldwide have significantly driven demand for LMWH-based therapies.

The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics.

Low Molecular Weight Heparin API segment market, the Enoxaparin Sodium holds an important share, and it is expected to reach a value of US$ 1,258.82 million by 2030, at a CAGR of 12.46% during 2024 and 2030.

The global key companies of Low Molecular Weight Heparin API include Yantai Dongcheng Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Changzhou Qianhong Biopharma, and Qingdao Jiulong Biopharmaceutical, etc. In 2023, the global five largest players hold a share approximately 72.91% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Low Molecular Weight Heparin API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Low Molecular Weight Heparin API by region & country, by Type, and by Application.

The Low Molecular Weight Heparin API market size, estimations, and forecasts are provided in terms of sales volume (Billion Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Low Molecular Weight Heparin API.

Market Segmentation

By Company

• Yantai Dongcheng Pharmaceutical
• Shenzhen Hepalink Pharmaceutical
• Nanjing King-friend
• Changzhou Qianhong Biopharma
• Qingdao Jiulong Biopharmaceutical
• Dongying Tiandong Pharmaceutical
• Yino Pharma
• Opocrin
• Hebei Changshan
• Hubei Enoray Biopharmaceutical
• Nanjing Nanda Pharmaceutical
• Cisen Pharmaceutical

Segment by Type

• Low Molecular Weight Heparin Sodium
• Low Molecular Weight Heparin Calcium

Segment by Application

• Enoxaparin Sodium
• Nadroparin Calcium
• Dalteparin Sodium
• Tinzaparin Sodium
• Parnaparin Sodium

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Low Molecular Weight Heparin API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Low Molecular Weight Heparin API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Low Molecular Weight Heparin API in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Low Molecular Weight Heparin API Product Introduction
• 1.2 Global Low Molecular Weight Heparin API Market Size Forecast
  • 1.2.1 Global Low Molecular Weight Heparin API Sales Value (2020-2031)
  • 1.2.2 Global Low Molecular Weight Heparin API Sales Volume (2020-2031)
  • 1.2.3 Global Low Molecular Weight Heparin API Sales Price (2020-2031)
• 1.3 Low Molecular Weight Heparin API Market Trends & Drivers
  • 1.3.1 Low Molecular Weight Heparin API Industry Trends
  • 1.3.2 Low Molecular Weight Heparin API Market Drivers & Opportunity
  • 1.3.3 Low Molecular Weight Heparin API Market Challenges
  • 1.3.4 Low Molecular Weight Heparin API Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Low Molecular Weight Heparin API Players Revenue Ranking (2024)
• 2.2 Global Low Molecular Weight Heparin API Revenue by Company (2020-2025)
• 2.3 Global Low Molecular Weight Heparin API Players Sales Volume Ranking (2024)
• 2.4 Global Low Molecular Weight Heparin API Sales Volume by Company Players (2020-2025)
• 2.5 Global Low Molecular Weight Heparin API Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Low Molecular Weight Heparin API Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Low Molecular Weight Heparin API Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Low Molecular Weight Heparin API
• 2.9 Low Molecular Weight Heparin API Market Competitive Analysis
  • 2.9.1 Low Molecular Weight Heparin API Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Low Molecular Weight Heparin API Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Low Molecular Weight Heparin API as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Low Molecular Weight Heparin Sodium
  • 3.1.2 Low Molecular Weight Heparin Calcium
• 3.2 Global Low Molecular Weight Heparin API Sales Value by Type
  • 3.2.1 Global Low Molecular Weight Heparin API Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Low Molecular Weight Heparin API Sales Value, by Type (2020-2031)
  • 3.2.3 Global Low Molecular Weight Heparin API Sales Value, by Type (%) (2020-2031)
• 3.3 Global Low Molecular Weight Heparin API Sales Volume by Type
  • 3.3.1 Global Low Molecular Weight Heparin API Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Low Molecular Weight Heparin API Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Low Molecular Weight Heparin API Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Low Molecular Weight Heparin API Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Enoxaparin Sodium
  • 4.1.2 Nadroparin Calcium
  • 4.1.3 Dalteparin Sodium
  • 4.1.4 Tinzaparin Sodium
  • 4.1.5 Parnaparin Sodium
• 4.2 Global Low Molecular Weight Heparin API Sales Value by Application
  • 4.2.1 Global Low Molecular Weight Heparin API Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Low Molecular Weight Heparin API Sales Value, by Application (2020-2031)
  • 4.2.3 Global Low Molecular Weight Heparin API Sales Value, by Application (%) (2020-2031)
• 4.3 Global Low Molecular Weight Heparin API Sales Volume by Application
  • 4.3.1 Global Low Molecular Weight Heparin API Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Low Molecular Weight Heparin API Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Low Molecular Weight Heparin API Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Low Molecular Weight Heparin API Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Low Molecular Weight Heparin API Sales Value by Region
  • 5.1.1 Global Low Molecular Weight Heparin API Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Low Molecular Weight Heparin API Sales Value by Region (2020-2025)
  • 5.1.3 Global Low Molecular Weight Heparin API Sales Value by Region (2026-2031)
  • 5.1.4 Global Low Molecular Weight Heparin API Sales Value by Region (%), (2020-2031)
• 5.2 Global Low Molecular Weight Heparin API Sales Volume by Region
  • 5.2.1 Global Low Molecular Weight Heparin API Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Low Molecular Weight Heparin API Sales Volume by Region (2020-2025)
  • 5.2.3 Global Low Molecular Weight Heparin API Sales Volume by Region (2026-2031)
  • 5.2.4 Global Low Molecular Weight Heparin API Sales Volume by Region (%), (2020-2031)
• 5.3 Global Low Molecular Weight Heparin API Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 5.4.2 North America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 5.5.2 Europe Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Low Molecular Weight Heparin API Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 5.7.2 South America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Low Molecular Weight Heparin API Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Low Molecular Weight Heparin API Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Low Molecular Weight Heparin API Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 6.3.2 United States Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 6.4.2 Europe Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 6.5.2 China Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 6.6.2 Japan Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 6.7.2 South Korea Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Low Molecular Weight Heparin API Sales Value, 2020-2031
  • 6.9.2 India Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Yantai Dongcheng Pharmaceutical
  • 7.1.1 Yantai Dongcheng Pharmaceutical Company Information
  • 7.1.2 Yantai Dongcheng Pharmaceutical Introduction and Business Overview
  • 7.1.3 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • 7.1.5 Yantai Dongcheng Pharmaceutical Recent Development
• 7.2 Shenzhen Hepalink Pharmaceutical
  • 7.2.1 Shenzhen Hepalink Pharmaceutical Company Information
  • 7.2.2 Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
  • 7.2.3 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • 7.2.5 Shenzhen Hepalink Pharmaceutical Recent Development
• 7.3 Nanjing King-friend
  • 7.3.1 Nanjing King-friend Company Information
  • 7.3.2 Nanjing King-friend Introduction and Business Overview
  • 7.3.3 Nanjing King-friend Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Nanjing King-friend Low Molecular Weight Heparin API Product Offerings
  • 7.3.5 Nanjing King-friend Recent Development
• 7.4 Changzhou Qianhong Biopharma
  • 7.4.1 Changzhou Qianhong Biopharma Company Information
  • 7.4.2 Changzhou Qianhong Biopharma Introduction and Business Overview
  • 7.4.3 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Product Offerings
  • 7.4.5 Changzhou Qianhong Biopharma Recent Development
• 7.5 Qingdao Jiulong Biopharmaceutical
  • 7.5.1 Qingdao Jiulong Biopharmaceutical Company Information
  • 7.5.2 Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
  • 7.5.3 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
  • 7.5.5 Qingdao Jiulong Biopharmaceutical Recent Development
• 7.6 Dongying Tiandong Pharmaceutical
  • 7.6.1 Dongying Tiandong Pharmaceutical Company Information
  • 7.6.2 Dongying Tiandong Pharmaceutical Introduction and Business Overview
  • 7.6.3 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • 7.6.5 Dongying Tiandong Pharmaceutical Recent Development
• 7.7 Yino Pharma
  • 7.7.1 Yino Pharma Company Information
  • 7.7.2 Yino Pharma Introduction and Business Overview
  • 7.7.3 Yino Pharma Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Yino Pharma Low Molecular Weight Heparin API Product Offerings
  • 7.7.5 Yino Pharma Recent Development
• 7.8 Opocrin
  • 7.8.1 Opocrin Company Information
  • 7.8.2 Opocrin Introduction and Business Overview
  • 7.8.3 Opocrin Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Opocrin Low Molecular Weight Heparin API Product Offerings
  • 7.8.5 Opocrin Recent Development
• 7.9 Hebei Changshan
  • 7.9.1 Hebei Changshan Company Information
  • 7.9.2 Hebei Changshan Introduction and Business Overview
  • 7.9.3 Hebei Changshan Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Hebei Changshan Low Molecular Weight Heparin API Product Offerings
  • 7.9.5 Hebei Changshan Recent Development
• 7.10 Hubei Enoray Biopharmaceutical
  • 7.10.1 Hubei Enoray Biopharmaceutical Company Information
  • 7.10.2 Hubei Enoray Biopharmaceutical Introduction and Business Overview
  • 7.10.3 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
  • 7.10.5 Hubei Enoray Biopharmaceutical Recent Development
• 7.11 Nanjing Nanda Pharmaceutical
  • 7.11.1 Nanjing Nanda Pharmaceutical Company Information
  • 7.11.2 Nanjing Nanda Pharmaceutical Introduction and Business Overview
  • 7.11.3 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • 7.11.5 Nanjing Nanda Pharmaceutical Recent Development
• 7.12 Cisen Pharmaceutical
  • 7.12.1 Cisen Pharmaceutical Company Information
  • 7.12.2 Cisen Pharmaceutical Introduction and Business Overview
  • 7.12.3 Cisen Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Cisen Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • 7.12.5 Cisen Pharmaceutical Recent Development

8 Industry Chain Analysis

• 8.1 Low Molecular Weight Heparin API Industrial Chain
• 8.2 Low Molecular Weight Heparin API Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Low Molecular Weight Heparin API Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Low Molecular Weight Heparin API Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer